UNSPSC 51181927: Clomifene citrate

This classification denotes an antiestrogen and angiogenesis activator inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1B8447E7YI. European Medicines Agency schedules Clomifene citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01360MIG. Clomiphene citrate generally arises in the molecular formula C32H36CLNO8. The term 'clomiphene citrate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule clomifene citrate under HS 29221980. SMILES:.

UNSPSC 51181927 Clomifene citrate is a Commodity code that encompasses specific pharmaceutical products being procured by state and local government health systems and cooperative purchasing alliances. State and local buyers under this code source branded and generic pharmaceuticals through cooperative purchasing vehicles and direct institutional procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body visible in recent activity, coordinating multi-state pharmaceutical procurement across participating state agencies, local government facilities, and health systems in Minnesota and Oregon. MMCAP structures these procurements as RFPs to establish blanket agreements with multiple manufacturers, requiring vendors to meet FDA compliance, current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, and extensive insurance coverage including $5,000,000 commercial general liability and $2,000,000 network security and privacy liability per occurrence.

MMCAP's January 2026 RFP for Generic Multi-Source Pharmaceuticals and OTC Products, due March 26, 2026, shows the scope of work: manufacturers must supply products with detailed National Drug Codes (NDC), SKUs, UPCs, and multiple pricing formats (flat price, net price, or WAC-minus structures) through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with all products available by May 15, 2026 and contracts effective July 1, 2026. Contract terms run two years for new responders with optional MMCAP extensions, or through June 30, 2028 for incumbent amendments. Evaluation weights heavily on price competitiveness (75 percent), with 10 percent on fixed pricing, 5 percent each on administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Vendors incur performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. No specific set-aside designations or disadvantaged-enterprise restrictions appear in the available documentation.